A Study to Determine the Feasibility of Treating Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Using Autologous NY-ESO-1 Specific CD8+ T Cells With Cyclophosphamide Pre-conditioning But Without the Use of IL-2

Trial Profile

A Study to Determine the Feasibility of Treating Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Using Autologous NY-ESO-1 Specific CD8+ T Cells With Cyclophosphamide Pre-conditioning But Without the Use of IL-2

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs NTBI 1301 (Primary) ; Cyclophosphamide
  • Indications Liposarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Oct 2015 Based upon the results of first 12 patients, the trial is expended to include 20 additional patients in 2 cohorts, as per Adaptimmune media release.
    • 05 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top